Literature DB >> 21499142

Lower incidence of transcranial Doppler and symptomatic vasospasm after aneurysmal subarachnoid hemorrhage and aneurysm clipping in the elderly patient?

Dorothee Wachter1, Franz Hans, Ilonka Kreitschmann-Andermahr, Veit Rohde.   

Abstract

BACKGROUND: Vasospasm is the major cause of morbidity and mortality after aneurysmal subarachnoid hemorrhage. It is well known that the vasoreactivity decreases with advancing age, but it is not well investigated in a large patient cohort whether, as a consequence, the incidence of vasospasm is lower in elderly patients.
OBJECTIVE: To investigate whether transcranial Doppler vasospasm, delayed ischemic neurological deficits, and vasospasm-associated ischemic lesions are less frequent in older patients.
METHODS: Seven hundred fifty-eight patients who suffered from subarachnoid hemorrhage were included in this study. Clinical presentation, Hunt and Hess score, Fisher grade, incidence of vasospasm, neurological deficits and ischemic lesions on radiographic imaging, transcranial Doppler blood flow velocities, medical complications, and outcome were registered.
RESULTS: Four hundred seventy-eight patients < 60 years of age and 280 patients ≥ 60 years of age were identified; 55.2% of the younger and 25.7% of the older age group developed post-hemorrhagic vasospasm (P < .001). Older patients developed less vasospasm (P = .00), fewer neurological deficits (P < .001), and fewer ischemic lesions on computed tomography imaging (P = .06). On the other hand, older patients had significantly worse outcomes than younger patients (P = .01) and more frequently died of medical complications (P = .01).
CONCLUSION: Vasospasm, delayed ischemic neurological deficits, and vasospasm-associated ischemic lesions are more likely to occur in patients < 60 years of age than in older patients. The lower incidence of vasospasm and vasospasm-related ischemia in the elderly patient does not translate into better outcome because of the higher rate of fatal medical complications in patients ≥ 60 years of age.

Entities:  

Mesh:

Year:  2011        PMID: 21499142     DOI: 10.1227/NEU.0b013e31821d2b49

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  6 in total

1.  Long-term outcomes among octogenarians with aneurysmal subarachnoid hemorrhage.

Authors:  Hormuzdiyar Dasenbrock; William B Gormley; Yoojin Lee; Vincent Mor; Susan L Mitchell; Corey R Fehnel
Journal:  J Neurosurg       Date:  2018-08-17       Impact factor: 5.115

2.  Identification of specific age groups with a high risk for developing cerebral vasospasm after aneurysmal subarachnoid hemorrhage.

Authors:  Vesna Malinova; Bawarjan Schatlo; Martin Voit; Patricia Suntheim; Veit Rohde; Dorothee Mielke
Journal:  Neurosurg Rev       Date:  2016-03-04       Impact factor: 3.042

3.  Systemic Immune-Inflammation Index Predicts Delayed Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage.

Authors:  Joseph R Geraghty; Tyler J Lung; Yonatan Hirsch; Eitan A Katz; Tiffany Cheng; Neil S Saini; Dilip K Pandey; Fernando D Testai
Journal:  Neurosurgery       Date:  2021-11-18       Impact factor: 5.315

4.  Neurointensive care results and risk factors for unfavorable outcome in aneurysmatic SAH: a comparison of two age groups.

Authors:  Teemu Luostarinen; Jarno Satopää; Vilja Välimäki; Rahul Raj; Jyri J Virta
Journal:  Acta Neurochir (Wien)       Date:  2021-01-29       Impact factor: 2.216

5.  Difference in Transcranial Doppler Velocity and Patient Age between Proximal and Distal Middle Cerebral Artery Vasospasms after Aneurysmal Subarachnoid Hemorrhage.

Authors:  Misaki Kohama; Shinichiro Sugiyama; Kenichi Sato; Hidenori Endo; Kuniyasu Niizuma; Toshiki Endo; Makoto Ohta; Yasushi Matsumoto; Miki Fujimura; Teiji Tominaga
Journal:  Cerebrovasc Dis Extra       Date:  2016-07-06

6.  Influence of Age-Related Complications on Clinical Outcome in Patients With Small Ruptured Cerebral Aneurysms.

Authors:  Jianfeng Zheng; Xiaochuan Sun; Xiaodong Zhang
Journal:  Front Neurol       Date:  2020-03-05       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.